Hims & Hers offers asymmetric digital-health growth through subscribers, GLP-1 distribution, Eucalyptus, and AI, but margin compression, regulatory litigation, leverage, and dilution make execution critical.
Overview
Hims & Hers is a consumer-first digital healthcare platform that provides consultations, prescriptions, and wellness products through mobile applications and websites, primarily on a recurring, cash-pay subscription basis. Its differentiation is built on convenience, privacy, transparent pricing, lifestyle branding, and personalized treatment combinations across men’s and women’s health. **The operating trajectory remains strong:** Q2 2026 revenue rose 38.2% year over year to $753.21 million, subscribers approached 2.9 million, monthly revenue per subscriber reached $92, and FY2026 revenue guidance increased to $3.1 billion-$3.3 billion. Eucalyptus drove international revenue above $131.4 million, while the Novo Nordisk agreement supports branded Ozempic, Wegovy, and oral Wegovy distribution. **Profitability is the central debate:** gross margin fell to 63.8% from 76.0%, Adjusted EBITDA margin declined to 8.0% from 15.1%, GAAP net loss was $86.29 million, and free cash flow was $(68.15) million. At $27.71, valuation is approximately 2.25x forward revenue and 2.64x price-to-sales, but regulatory lawsuits, $1.37 billion of convertible notes, dilution, and margin pressure explain the Hold consensus and create substantial scenario dispersion.